Investors

Corporate Profile

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and...
More

Stock Quote
XTNT (Common Stock)
Price$0.68
Change (%) + 0.02 (3.03%)
Volume823,945
Data as of 12/09/16 4:02 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: XTNT.K.  Currently trading at $0.68 with a 52 week high of $3.75 and a 52 week low of $0.45.
Recent News
DateTitle 
11/23/16Xtant Medical Receives FDA Clearance for the Xsert™ Lumbar Expandable Interbody System
BELGRADE, Mont., Nov. 23, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Xsert Lumbar Expandable Interbody System. The Xsert System is an all titanium expandable interbody device that expands in-situ. It is available in various sizes and lordotic angulations to fit the most complex anatomical needs of pati... 
11/17/16Xtant Medical Closes Rights Offering for Gross Proceeds of $3.8 Million
BELGRADE, Mont., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today the closing of its rights offering (the "Offering") of units at a subscription price of $0.75 per unit, for aggregate gross proceeds to the Company of approximately $3.8 million. Pursuant to the Rights Offering, Xtant sold an aggregate of 5,055,345 units consistin... 
11/15/16Xtant Medical Announces Expiration of Rights Offering and Estimated Gross Proceeds of $3.8 Million
BELGRADE, Mont., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that the subscription period for its previously announced rights offering (the "Offering") of units at a subscription price of $0.75 per unit expired on November 14, 2016, and these rights are no longer exercisable. Based on the review of results provided by the... 
11/15/16Xtant Medical Receives FDA Clearance to Use Allografts in the Stand-Alone Irix-C™ Cervical Cage
BELGRADE, Mont., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Irix-C cervical cage for use with autograft and/or allograft and the expansion of the range of levels allowable from C3-T1 to C2-T1. Previously the device was cleared only for use with autogenous bone graft. This furthers Xtant Medical's... 
More

Upcoming Events
There are currently no events scheduled.
More

Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Xtant Medical Holdings Inc posts new information to the site. Just enter your e-mail address and click Submit.